

**Supplementary Table 1.** Members of the Drug-Induced Liver Injury Network: 2004–2015

University of Connecticut (site 101): Herbert Bonkovsky, MD, PI; Petr Protiva, MD, co-PI; James Freston, MD, PhD, co-PI; Robert Rosson, MD, co-PI; Robert A. Levine, MD (Satellite site investigator); Benedict Maliakkal, MD (Satellite site investigator); [Paul Appleton, MD, Study Coordinator; Mariola Smialek, RN, Research Coordinator].

Indiana University-Purdue (site 102): Naga Chalasani, MD, PI; Marwan S. Ghabril, MD, Sub-I; Suthat Liangpunsakul, MD, Sub-I; Raj Vuppalanchi, MD, Sub-I; [Audrey Come, RN, EdD, Study Coordinator; Sherrie Cummings, RN, BSN, Study Coordinator; Wendy Morlan, RN, Study Coordinator].

California Pacific Medical Center Liver Transplant Program (site 103): Tim Davern, MD, (PI); Maurice Bonacini, MD, co-PI; [Katharine Fajardo, Study Coordinator; Anthony Nguyen, Study Coordinator].

University of Michigan-Ann Arbor (site 104): Robert J. Fontana, MD, PI; Hari Conjeevaram, MD, Sub-I; Frank DiPaola, MD, Sub-I; [Cassandra Coffman, Study Coordinator; Sophana Mao, Study Coordinator].

University of North Carolina-Chapel Hill (site 105): Paul Watkins, MD, PI; Jama Darling, MD, Sub-I; Michael Fried, Sub-I; Paul H. Hayashi, MD, Sub-I; Steven Lichtman, MD, Sub-I; Steven Zacks, MD, MPH, Sub-I; [Tracy Russell, CCRP, Study Coordinator].

Satellite Sites

Asheville: William Harlan, MD, PI; [Tracy Russell, CCRP, Study Coordinator];

Wake Forest Baptist Medical Center: Herbert Bonkovsky, MD, PI; Pradeep Yarra, MD, Sub-I; [Denise Faust, Study Coordinator].

University of Texas Southwestern Medical Center (site 106): William Lee, MD, PI; LaFaine Grant, MD, co-PI; Mamta Jain, MD, Sub-I; [Theresa Hardwick, RN, CCRC, Study Coordinator; Stacey Minshall, RN, BSN, Study Coordinator; Suraj Naik, MD, Study Coordinator].

University of Southern California (site 107): Andrew Stolz, MD, PI; Neil Kaplowitz, MD, Sub-I; [Susan Milstein, RN, BSN, Study Coordinator].

Satellite Sites

University of California-Los Angeles (Pfleger Liver Institute): Francisco A. Durazo, MD, PI; [Yolanda Melgoza, Study Coordinator; Val Peacock, RN, BSN, Co-Coordinator].

Mayo Clinic (site 108): Jayant Talwalkar, MD, PI; John Poterucha, MD, Sub-I; Deborah Freese, MD, Sub-I; Timothy Aksamit, MD, Sub-I; [Stephanie Johnson, BSN, RN, CCRC, Study Coordinator].

Albert Einstein Medical Center (site 109): Victor J. Navarro, MD, PI; Simona Rossi, MD, Sub-I; [Maricruz Vega, MPH, Study Coordinator; Manisha Verma, MD, MPH, Study Coordinator].

Icahn School of Medicine at Mount Sinai (site 110): Joseph Odin, MD, PhD, PI; Jawad Ahmad, MD, PI; Nancy Bach, Sub-I; Meena Bansal, MD, Sub-I; Charissa Chang, MD, Sub-I; Douglas Dieterich, MD, Sub-I; Priya Grewal, MD, Sub-I; Lawrence Liu, MD, Sub-I; Thomas Schiano, MD, Sub-I; [Monica Taveras, Study Coordinator].

1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276

Supplementary Table 2. ■■■

Q8 1340

Feature	Augmentin (n = 33)	Isoniazid (n = 24)	Diclofenac (n = 10)
Age (y) <sup>a</sup>	57 (36–76)	46 (17–70)	48 (32–65)
Female sex	11 (33%)	17 (71%)	8 (80%)
Race			
White	33 (100%)	15 (63%)	8 (80%)
Black	0 (0%)	3 (13%)	1 (10%)
Other	0 (0%)	6 (24%)	1 (10%)
BMI (kg/m <sup>2</sup> ) <sup>a</sup>	26 (18–40)	25 (19–41)	30 (25–42)
Latency (mo)			
<1	19 (58%)	0 (0%)	3 (30%)
1–6	14 (42%)	20 (83%)	5 (50%)
6–12	0 (0%)	4 (17%)	1 (10%)
>12	0 (0%)	0 (0%)	1 (10%)
Initial results			
ALT (U/L) <sup>a</sup>	387 (98–1843)	849 (56–3770)	842 (249–2720)
AST (U/L) <sup>a</sup>	146 (47–847)	755 (111–3750)	585 (155–1872)
Alk P (U/L) <sup>a</sup>	249 (145–576)	172 (58–432)	179 (103–297)
R ratio <sup>a,b</sup>	2.7 (1.1–14.7)	13.2 (2.2–76.1)	14.5 (5.1–31.2)
Bilirubin (mg/dL)	5.8 (1.8–13.5)	3.8 (0.3–26.7)	1.7 (0.4–33.4)
Pattern of injury <sup>b</sup>			
Hepatocellular	8 (25%)	17 (81%)	10 (100%)
Mixed	19 (59%)	4 (19%)	0
Cholestatic	5 (16%)	0 (0%)	0
Symptoms, signs			
Jaundice	30 (91%)	12 (50%)	6 (60%)
Itching	31 (94%)	6 (25%)	4 (40%)
Rash	5 (15%)	2 (8%)	4 (40%)
Fever	4 (12%)	5 (21%)	3 (30%)
Eosinophilia	5 (16%)	2 (9%)	1 (10%)
Autoimmune features			
ANA	3 (9%)	7 (29%)	5 (50%)
SMA	1 (3%)	5 (21%)	3 (30%)
IgG >ULN	2 (6%)	1 (4%)	3 (30%)
Phenotype			
Immunoallergic	4 (13%)	2 (9%)	3 (30%)
Autoimmune	2 (6%)	4 (17%)	4 (40%)

BMI, body mass index.

<sup>a</sup>Median (range).<sup>b</sup>R ratio = (ALT/ULN) ÷ (Alk P/ULN). Hepatocellular, R ratio >5; Mixed, R ratio 2–5; Cholestatic, R ratio <2.